{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:42:00Z","timestamp":1790613720699,"version":"4.1.0"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["109-2221-E-037-001-MY3"],"award-info":[{"award-number":["109-2221-E-037-001-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["NSTC 113-2314-B-037-026-MY3"],"award-info":[{"award-number":["NSTC 113-2314-B-037-026-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018811","name":"National Pingtung University of Science and Technology","doi-asserted-by":"publisher","award":["KMU-114-P002"],"award-info":[{"award-number":["KMU-114-P002"]}],"id":[{"id":"10.13039\/100018811","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["KMUH114-4R40"],"award-info":[{"award-number":["KMUH114-4R40"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["KMUH113-3R36"],"award-info":[{"award-number":["KMUH113-3R36"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011645","name":"Kaohsiung Medical University Chung-Ho Memorial Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.nano.2026.102907","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T16:42:49Z","timestamp":1770136969000},"page":"102907","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Theranostic application of 131I-labeled anti-glypican-3 antibody for targeted radioimmunotherapy in hepatocellular carcinoma"],"prefix":"10.1016","volume":"72","author":[{"given":"Ming-Hui","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Pin","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Rou","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Chiao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Chang","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Chuan","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Fong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Hui","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chang","family":"Tyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nano.2026.102907_bb0005","first-page":"1","article-title":"Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification","volume":"149","author":"Chidambaranathan-Reghupaty","year":"2021","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.nano.2026.102907_bb0010","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.cld.2015.01.001","article-title":"Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability","volume":"19","author":"McGlynn","year":"2015","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.nano.2026.102907_bb0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14740\/wjon1166","article-title":"Epidemiology of pancreatic cancer: global trends, etiology and risk factors","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"key":"10.1016\/j.nano.2026.102907_bb0020","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/SLA.0000000000002135","article-title":"Incidence of occult intrahepatic metastasis in hepatocellular carcinoma treated with transplantation corresponds to early recurrence rates after partial hepatectomy","volume":"267","author":"Aufhauser","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.nano.2026.102907_bb0025","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.nano.2026.102907_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110797","article-title":"The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma","volume":"132","author":"Wang","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.nano.2026.102907_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110682","article-title":"Enhanced targeted delivery of adenine to hepatocellular carcinoma using glycyrrhetinic acid-functionalized nanoparticles in vivo and in vitro","volume":"131","author":"Wu","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.nano.2026.102907_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2019.114607","article-title":"Tumor suppressor gene glycine N-methyltransferase and its potential in liver disorders and hepatocellular carcinoma","volume":"378","author":"Chen","year":"2019","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.nano.2026.102907_bb0045","doi-asserted-by":"crossref","first-page":"5645","DOI":"10.2147\/IJN.S115727","article-title":"Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma","volume":"11","author":"Li","year":"2016","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.nano.2026.102907_bb0050","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.canlet.2017.12.023","article-title":"Targeted co-delivery of epirubicin and NAS-24 aptamer to cancer cells using selenium nanoparticles for enhancing tumor response in vitro and in vivo","volume":"416","author":"Jalalian","year":"2018","journal-title":"Cancer Lett"},{"key":"10.1016\/j.nano.2026.102907_bb0055","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.canlet.2019.01.032","article-title":"Drug delivery systems targeting tumor-associated fibroblasts for cancer immunotherapy","volume":"448","author":"Liu","year":"2019","journal-title":"Cancer Lett"},{"key":"10.1016\/j.nano.2026.102907_bb0060","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jconrel.2019.06.023","article-title":"The hepatic-targeted, resveratrol loaded nanoparticles for relief of high fat diet-induced nonalcoholic fatty liver disease","volume":"307","author":"Teng","year":"2019","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2026.102907_bb0065","article-title":"Benchmarking comparison of chimeric antigen receptor targets in hepatocellular carcinoma: a multimodal analysis","volume":"Engl","author":"Tang","year":"2025","journal-title":"Chin Med J"},{"key":"10.1016\/j.nano.2026.102907_bb0070","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/s40001-024-02073-2","article-title":"The role of glypican-3 in hepatocellular carcinoma: insights into diagnosis and therapeutic potential","volume":"29","author":"Devan","year":"2024","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.nano.2026.102907_bb0075","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1369\/0022155420933709","article-title":"The role of Glypicans in cancer progression and therapy","volume":"68","author":"Li","year":"2020","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.nano.2026.102907_bb0080","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.devcel.2008.03.006","article-title":"Glypican-3 inhibits hedgehog signaling during development by competing with patched for hedgehog binding","volume":"14","author":"Capurro","year":"2008","journal-title":"Dev Cell"},{"key":"10.1016\/j.nano.2026.102907_bb0085","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.7150\/jca.39972","article-title":"Glypican-3: a new target for diagnosis and treatment of hepatocellular carcinoma","volume":"11","author":"Guo","year":"2020","journal-title":"J Cancer"},{"key":"10.1016\/j.nano.2026.102907_bb0090","first-page":"703","article-title":"Diagnostic value of glypican-3 in alpha fetoprotein negative hepatocellular carcinoma patients","volume":"13","author":"Li","year":"2013","journal-title":"Afr Health Sci"},{"key":"10.1016\/j.nano.2026.102907_bb0095","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3390\/cells14100726","article-title":"Unraveling glypican-3: from structural to pathophysiological roles and mechanisms-an integrative perspective","volume":"14","author":"Piao","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.nano.2026.102907_bb0100","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1038\/s41598-021-82172-w","article-title":"Glypican-3 targeted delivery of 89Zr and 90Y as a theranostic radionuclide platform for hepatocellular carcinoma","volume":"11","author":"Labadie","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.nano.2026.102907_bb0105","doi-asserted-by":"crossref","first-page":"536","DOI":"10.7150\/ijbs.64537","article-title":"The landscape of alpha fetoprotein in hepatocellular carcinoma: where are we?","volume":"18","author":"Hu","year":"2022","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.nano.2026.102907_bb0110","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/ijc.24941","article-title":"Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo","volume":"126","author":"Zittermann","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.nano.2026.102907_bb0115","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/1724600818784409","article-title":"Diagnosis accuracy of serum glypican-3 level in patients with hepatocellular carcinoma: a systematic review with meta-analysis","volume":"33","author":"Li","year":"2018","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.nano.2026.102907_bb0120","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1002\/ijc.29518","article-title":"High preoperative levels of serum glypican-3 containing N-terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy","volume":"137","author":"Haruyama","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.nano.2026.102907_bb0125","first-page":"811","article-title":"Diagnostic value of glypican-3 for hepatocellular carcinomas","volume":"19","author":"El-Saadany","year":"2018","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.nano.2026.102907_bb0130","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/med.21455","article-title":"Glypican-3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment","volume":"38","author":"Zhou","year":"2018","journal-title":"Med Res Rev"},{"key":"10.1016\/j.nano.2026.102907_bb0135","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1021\/acs.biochem.7b01208","article-title":"Role of Glycanation and convertase maturation of soluble glypican-3 in inhibiting proliferation of hepatocellular carcinoma cells","volume":"57","author":"Saad","year":"2018","journal-title":"Biochemistry"},{"key":"10.1016\/j.nano.2026.102907_bb0140","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ymeth.2018.10.005","article-title":"Engineering a bispecific antibody with a common light chain: identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974","volume":"154","author":"Shiraiwa","year":"2019","journal-title":"Methods"},{"key":"10.1016\/j.nano.2026.102907_bb0145","first-page":"7422","article-title":"Anti-GPC3 single-chain scFv antibody acts as an agent for radio-immunoimaging in diagnosing hepatocellular carcinoma","volume":"11","author":"Guan","year":"2019","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.nano.2026.102907_bb0150","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrc3925","article-title":"Radioimmunotherapy of human tumours","volume":"15","author":"Larson","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.nano.2026.102907_bb0155","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.3390\/cancers14061454","article-title":"Radiolabeled antibodies for cancer imaging and therapy","volume":"14","author":"Parakh","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.nano.2026.102907_bb0160","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s13139-021-00703-9","article-title":"KSNM60 in non-thyroidal radionuclide therapy: leaping into the future","volume":"55","author":"Byun","year":"2021","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1016\/j.nano.2026.102907_bb0165","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20180103","article-title":"MIBG (metaiodobenzylguanidine) theranostics in pediatric and adult malignancies","volume":"91","author":"Agrawal","year":"2018","journal-title":"Br J Radiol"},{"key":"10.1016\/j.nano.2026.102907_bb0170","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s13139-018-0523-z","article-title":"Current consensus on I-131 MIBG therapy","volume":"52","author":"Kayano","year":"2018","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1016\/j.nano.2026.102907_bb0175","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1245\/s10434-014-3511-2","article-title":"Systematic review and meta-analysis of adjuvant I(131) lipiodol after excision of hepatocellular carcinoma","volume":"21","author":"Furtado","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.nano.2026.102907_bb0180","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/978-1-61779-974-7_38","article-title":"Radiolabeled antibodies for cancer imaging and therapy","volume":"907","author":"Barbet","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.nano.2026.102907_bb0185","article-title":"Preparation and characterization of hyaluronic acid-polycaprolactone copolymer micelles for the drug delivery of radioactive iodine-131 labeled lipiodol","volume":"2017","author":"Chen","year":"2017","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.nano.2026.102907_bb0190","first-page":"552","article-title":"Alterations of methionine metabolism in hepatocarcinogenesis: the emergent role of glycine N-methyltransferase in liver injury","volume":"31","author":"Simile","year":"2018","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.nano.2026.102907_bb0195","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.apradiso.2009.09.021","article-title":"Neutron radiography using neutron imaging plate","volume":"68","author":"Chankow","year":"2010","journal-title":"Appl Radiat Isot"},{"key":"10.1016\/j.nano.2026.102907_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.radmeas.2020.106511","article-title":"Development of an alpha- and beta-imaging detector using a thin-stilbene plate for radon-222 progeny measurements","volume":"140","author":"Morishita","year":"2021","journal-title":"Radiat Meas"},{"key":"10.1016\/j.nano.2026.102907_bb0205","first-page":"665","article-title":"Targeting glypican-3 for liver cancer therapy: clinical applications and detection methods","volume":"13","author":"Zhang","year":"2025","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.nano.2026.102907_bb0210","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/hep.30326","article-title":"Glypican-3-specific antibody drug conjugates targeting hepatocellular carcinoma","volume":"70","author":"Fu","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.nano.2026.102907_bb0215","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s13181-014-0412-5","article-title":"Evaluation of toxicological hazards from medical radioiodine administration","volume":"11","author":"Van Dyke","year":"2015","journal-title":"J Med Toxicol"},{"key":"10.1016\/j.nano.2026.102907_bb0220","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1038\/s41467-024-46321-9","article-title":"Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria","volume":"15","author":"Foss","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.nano.2026.102907_bb0225","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.3748\/wjg.v20.i8.2113","article-title":"Pleomorphic hepatocellular carcinoma following consumption of hypericum perforatum in alcoholic cirrhosis","volume":"20","author":"Lampri","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.nano.2026.102907_bb0230","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3390\/mi10020156","article-title":"Multinucleation of incubated cells and their morphological differences compared to mononuclear cells","volume":"10","author":"Sugita","year":"2019","journal-title":"Micromachines (Basel)"},{"key":"10.1016\/j.nano.2026.102907_bb0235","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2022-001013","article-title":"New case of syncytial giant-cell variant of hepatocellular carcinoma in a pediatric patient with HNF1B deficiency: does it fit with the syndrome?","volume":"9","author":"Pinon","year":"2022","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.nano.2026.102907_bb0240","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4161\/mabs.3.2.14239","article-title":"Monoclonal antibodies in neuro-oncology: getting past the blood-brain barrier","volume":"3","author":"Lampson","year":"2011","journal-title":"MAbs"},{"key":"10.1016\/j.nano.2026.102907_bb0245","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cytogfr.2025.12.006","article-title":"Combination therapy strategies targeting glypican-3 in hepatocellular carcinoma: a comprehensive review","volume":"87","author":"Nabiyi","year":"2025","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.nano.2026.102907_bb0250","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.3390\/ijerph110404158","article-title":"Managing terrorism or accidental nuclear errors, preparing for iodine-131 emergencies: a comprehensive review","volume":"11","author":"Braverman","year":"2014","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.nano.2026.102907_bb0255","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s12020-017-1461-8","article-title":"Lugol's solution and other iodide preparations: perspectives and research directions in Graves' disease","volume":"58","author":"Calissendorff","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.nano.2026.102907_bb0260","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1007\/s00259-010-1545-7","article-title":"131I\/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging","volume":"37","author":"Bombardieri","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nano.2026.102907_bb0265","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.2967\/jnumed.109.066993","article-title":"Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis","volume":"50","author":"Santoro","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nano.2026.102907_bb0270","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3892\/or.2014.3300","article-title":"GPC3 expression in mouse ovarian cancer induces GPC3specific T cell-mediated immune response through M1 macrophages and suppresses tumor growth","volume":"32","author":"Luo","year":"2014","journal-title":"Oncol Rep"},{"key":"10.1016\/j.nano.2026.102907_bb0275","doi-asserted-by":"crossref","first-page":"10185","DOI":"10.4238\/2015.August.28.2","article-title":"Differential expression of glypican-3 (GPC3) in lung squamous cell carcinoma and lung adenocarcinoma and its clinical significance","volume":"14","author":"Yu","year":"2015","journal-title":"Genet Mol Res"},{"key":"10.1016\/j.nano.2026.102907_bb0280","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/annonc\/mdu524","article-title":"Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study","volume":"26","author":"Jackisch","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.nano.2026.102907_bb0285","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/annonc\/mdu364","article-title":"Patients\u2019 preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study","volume":"25","author":"Pivot","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.nano.2026.102907_bb0290","first-page":"923","article-title":"The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection","volume":"9","author":"Jin","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.nano.2026.102907_bb0295","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.nano.2026.102907_bb0300","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cgh.2013.10.038","article-title":"Update on biomarkers of hepatocellular carcinoma","volume":"13","author":"Chaiteerakij","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.nano.2026.102907_bb0305","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.cgh.2014.02.025","article-title":"Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis","volume":"12","author":"Del Poggio","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.nano.2026.102907_bb0310","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.nano.2026.102907_bb0315","doi-asserted-by":"crossref","first-page":"516","DOI":"10.14218\/JCTH.2024.00018","article-title":"Ultrasonography of hepatocellular carcinoma: from diagnosis to prognosis","volume":"12","author":"Hu","year":"2024","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.nano.2026.102907_bb0320","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1148\/radiol.14132362","article-title":"CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. extracellular agents, hepatobiliary agents, and ancillary imaging features","volume":"273","author":"Choi","year":"2014","journal-title":"Radiology"},{"key":"10.1016\/j.nano.2026.102907_bb0325","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nano.2026.102907_bb0330","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1634\/theoncologist.2011-0465","article-title":"Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma","volume":"17","author":"Boige","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.nano.2026.102907_bb0335","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.nano.2026.102907_bb0340","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS4152","article-title":"Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): phase 3 LEAP-002 study","volume":"37","author":"Llovet","year":"2019","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.nano.2026.102907_bb0345","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4274\/2017.26.suppl.07","article-title":"I-124 imaging and dosimetry","volume":"26","author":"Kuker","year":"2017","journal-title":"Mol Imaging Radionucl Ther"},{"key":"10.1016\/j.nano.2026.102907_bb0350","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2967\/jnumed.110.086165","article-title":"(124)I-huA33 antibody PET of colorectal cancer","volume":"52","author":"Carrasquillo","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nano.2026.102907_bb0355","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.2011.41.2445","article-title":"Positron emission tomography\/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial","volume":"31","author":"Divgi","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nano.2026.102907_bb0360","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13550-018-0374-8","article-title":"I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma","volume":"8","author":"Carrasquillo","year":"2018","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.nano.2026.102907_bb0365","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(14)70131-7","article-title":"Conventional stents versus stents loaded with (125)iodine seeds for the treatment of unresectable oesophageal cancer: a multicentre, randomised phase 3 trial","volume":"15","author":"Zhu","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.nano.2026.102907_bb0370","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jhep.2017.12.028","article-title":"Irradiation stents vs. conventional metal stents for unresectable malignant biliary obstruction: a multicenter trial","volume":"68","author":"Zhu","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.nano.2026.102907_bb0375","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20180136","article-title":"Differentiated thyroid cancer theranostics: radioiodine and beyond","volume":"91","author":"Choudhury","year":"2018","journal-title":"Br J Radiol"},{"key":"10.1016\/j.nano.2026.102907_bb0380","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/j.semnuclmed.2011.07.004","article-title":"Imaging of the thyroid in benign and malignant disease","volume":"42","author":"Intenzo","year":"2012","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.nano.2026.102907_bb0385","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2174\/1874471009666161028150654","article-title":"Gallium-68 in medical imaging","volume":"9","author":"Martiniova","year":"2016","journal-title":"Curr Radiopharm"},{"key":"10.1016\/j.nano.2026.102907_bb0390","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1097\/MNM.0b013e328365d99b","article-title":"Pilot study of 68Ga-DOTA-F(ab\u2019)2-trastuzumab in patients with breast cancer","volume":"34","author":"Beylergil","year":"2013","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.nano.2026.102907_bb0395","doi-asserted-by":"crossref","DOI":"10.1177\/1533033819830758","article-title":"64Cu-based radiopharmaceuticals in molecular imaging","volume":"18","author":"Zhou","year":"2019","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.nano.2026.102907_bb0400","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S2468-1253(21)00305-8","article-title":"Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial","volume":"6","author":"Tai","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.nano.2026.102907_bb0405","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.nano.2026.102907_bb0410","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/203601","article-title":"Zirconium-89 labeled antibodies: a new tool for molecular imaging in cancer patients","volume":"2014","author":"van de Watering","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.nano.2026.102907_bb0415","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1016\/j.biomaterials.2014.04.089","article-title":"Imaging of hepatocellular carcinoma patient-derived xenografts using 89Zr-labeled anti-glypican-3 monoclonal antibody","volume":"35","author":"Yang","year":"2014","journal-title":"Biomaterials"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963426000080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963426000080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:33:14Z","timestamp":1778617994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963426000080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":83,"alternative-id":["S1549963426000080"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2026.102907","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Theranostic application of 131I-labeled anti-glypican-3 antibody for targeted radioimmunotherapy in hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2026.102907","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102907"}}